Details of Disease

Disease Name

Non-small-cell lung cancer

Disease Class

2C25: Non-small-cell lung cancer

Disease Hierarchy

DIS01GPL: Grass pollen hypersensitivity

DISI0V1B: Non-small-cell lung cancer

ICD-11

ICD-11: 2C25

Disease Identifiers

MONDO ID

MONDO_0005233

MESH ID

D002289

UMLS CUI

C0007131

MedGen ID

40104

HPO ID

HP:0030358

Orphanet ID

488201

SNOMED CT ID

254637007

General Information of Disease (ID: DISI0V1B)

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 11 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Adagrasib	DMDV4EP	Approved	Small molecular drug	[1]
Amivantamab	DMZ7AMY	Approved	Antibody	[2]
Atezolizumab	DMMF8U0	Approved	Monoclonal antibody	[3]
Entrectinib	DMMPTLH	Approved	Small molecular drug	[4]
Gemcitabine	DMSE3I7	Approved	Small molecular drug	[5]
Mobocertinib	DMFWE9S	Approved	Small molecular drug	[6]
Repotrectinib	DM9FB2T	Approved	NA	[7]
Sacituzumab govitecan	DMUWFD8	Approved	Antibody drug conjugate	[8]
Sotorasib	DMLSV74	Approved	Small molecular drug	[9]
Sugemalimab	DMH5YQ3	Approved in China	Monoclonal antibody	[10]
Tepotinib	DMUQ0E8	Approved	Small molecular drug	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 Drug(s)

This Disease is Treated as An Indication in 40 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AB154	DMUES7Y	Phase 3	Antibody	[12]
CS1001	DMSY0NE	Phase 3	Antibody	[13]
Datopotamab deruxtecan	DMO4GTC	Phase 3	Antibody drug conjugate	[14]
JDQ443	DMHI7CQ	Phase 3	Small molecule	[15]
MYL-1402O	DMXN2PP	Phase 3	Antibody	[16]
RG6058	DMOOHOT	Phase 3	Antibody	[17]
TRS003	DMM1VOH	Phase 3	Antibody	[18]
Tusamitamab ravtansine	DMMPSA1	Phase 3	Antibody drug conjugate	[19]
AB-106	DMEW62S	Phase 2	Small molecular drug	[20]
APL-101	DMP0LST	Phase 2	Small molecular drug	[21]
AZD7789	DMOIHWI	Phase 2	Antibody	[22]
Bintrafusp alfa	DMB9LRJ	Phase 2	Recombinant protein	[23]
BNT116	DM741KF	Phase 2	Vaccine	[24]
GSK4069889	DMV6SNU	Phase 2	Antibody	[25]
L-DOS47	DMIEZUB	Phase 2	NA	[26]
NC318	DMT6O2E	Phase 2	Antibody	[27]
RO-5126766	DM3U9BY	Phase 2	Small molecular drug	[28]
SGN-LIV1A	DMA4LNE	Phase 2	Antibody drug conjugate	[29]
Vorolanib	DMIM1U9	Phase 2	Small molecular drug	[30]
Voyager-V1	DMNUDO0	Phase 2	Oncolytic virus therapy	[31]
Xofigo	DMHL5M4	Phase 2	NA	[32]
BGB-A425	DMI42Q0	Phase 1/2	Antibody	[33]
DZD9008	DM72DU3	Phase 1/2	Small molecular drug	[34]
EMB-01	DMCAUKW	Phase 1/2	Antibody	[35]
IK-007	DMBLFPN	Phase 1/2	NA	[36]
MRx0518	DMYO3PW	Phase 1/2	Live biotherapeutic product	[37]
NM21-1480	DMDNJP5	Phase 1/2	Antibody	[38]
Rilvegostomig	DMDWCM2	Phase 1/2	Bispecific antibody	[39]
TC-210	DM9S5I1	Phase 1/2	TCR-T cell therapy	[40]
ADP-A2M10	DM8BOFB	Phase 1	CAR-T cell therapy	[41]
AMG 160	DMM0HNF	Phase 1	Antibody	[42]
Cosibelimab	DMULBZM	Phase 1	Antibody	[43]
ENV-105	DMC1SRK	Phase 1	Antibody	[44]
GEM3PSCA	DM3GSPR	Phase 1	Antibody	[45]
GEN-011	DMNELKW	Phase 1	Cell therapy	[46]
IBI318	DMB83V4	Phase 1	Antibody	[47]
MEDI5752	DMJ1E24	Phase 1	Antibody	[48]
PF-06936308	DM4SCKT	Phase 1	Vaccine	[49]
PF-07104091	DMMJZ2E	Phase 1	Small molecular drug	[50]
PF-07257876	DM0E2SW	Phase 1	Antibody	[51]
------------------------------------------------------------------------------------


⏷ Show the Full List of 40 Drug(s)

This Disease is Treated as An Indication in 1 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
SMI-4a	DMBLWMS	Investigative	Small molecular drug	[52]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216340.
2	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761210.
3	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
4	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
5	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
6	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215310.
7	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218213
8	ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health.
9	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214665.
10	Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
11	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
12	ClinicalTrials.gov (NCT04736173) Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer. U.S. National Institutes of Health.
13	ClinicalTrials.gov (NCT03728556) A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
14	ClinicalTrials.gov (NCT05555732) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07). U.S.National Institutes of Health.
15	ClinicalTrials.gov (NCT05132075) A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. U.S.National Institutes of Health.
16	ClinicalTrials.gov (NCT04633564) Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin?, in the First-line Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
17	ClinicalTrials.gov (NCT04294810) A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01). U.S. National Institutes of Health.
18	ClinicalTrials.gov (NCT04416035) A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC. U.S.National Institutes of Health.
19	ClinicalTrials.gov (NCT05245071) Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA. U.S.National Institutes of Health.
20	ClinicalTrials.gov (NCT04395677) A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene. U.S. National Institutes of Health.
21	ClinicalTrials.gov (NCT04258033) A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation. U.S. National Institutes of Health.
22	ClinicalTrials.gov (NCT04931654) A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
23	ClinicalTrials.gov (NCT04560686) Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer. U.S. National Institutes of Health.
24	ClinicalTrials.gov (NCT05557591) A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 >=50%. U.S.National Institutes of Health.
25	ClinicalTrials.gov (NCT04655976) Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung). U.S. National Institutes of Health.
26	ClinicalTrials.gov (NCT02340208) A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47. U.S. National Institutes of Health.
27	ClinicalTrials.gov (NCT04699123) The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
28	ClinicalTrials.gov (NCT04625270) A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. U.S. National Institutes of Health.
29	ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
30	ClinicalTrials.gov (NCT03848611) CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).. U.S. National Institutes of Health.
31	ClinicalTrials.gov (NCT04291105) Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients. U.S. National Institutes of Health.
32	ClinicalTrials.gov (NCT02283749) BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases. U.S.National Institutes of Health.
33	ClinicalTrials.gov (NCT03744468) Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health.
34	ClinicalTrials.gov (NCT03974022) Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1). U.S. National Institutes of Health.
35	ClinicalTrials.gov (NCT03797391) A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.
36	ClinicalTrials.gov (NCT03696212) Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma. U.S.National Institutes of Health.
37	ClinicalTrials.gov (NCT03637803) Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors. U.S. National Institutes of Health.
38	ClinicalTrials.gov (NCT04442126) A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
39	ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
40	ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
41	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.
42	ClinicalTrials.gov (NCT04822298) Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
43	ClinicalTrials.gov (NCT04786964) Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO). U.S. National Institutes of Health.
44	ClinicalTrials.gov (NCT05401110) IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
45	ClinicalTrials.gov (NCT03927573) Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker. U.S. National Institutes of Health.
46	ClinicalTrials.gov (NCT04596033) TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy. U.S. National Institutes of Health.
47	ClinicalTrials.gov (NCT04777084) The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.. U.S. National Institutes of Health.
48	ClinicalTrials.gov (NCT03819465) A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN). U.S. National Institutes of Health.
49	ClinicalTrials.gov (NCT03674827) Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC. U.S. National Institutes of Health.
50	ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
51	ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
52	Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050.